You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The assay underwent clinical validation at three centers in Singapore and 5,248 patients were ultimately screened using the test.
The firm reported $2 billion in third-quarter revenues related to the COVID-19 response, accounting for 23 percent of its overall revenues.
The company reported net income of $1.93 billion, or $4.84 per share, compared to $760 million, or $1.89 per share, for the year-ago quarter.
The effort, called INNO4COV-19, was awarded €6.1 million last month to support the commercialization of new diagnostics.
The firm said its coronavirus assay targets the nucleocapsid and envelope virus genes and is compatible with most RNA extraction methods and qPCR instruments.
Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased.
Roche will have non-exclusive access to SpeeDx's existing tests and technology to enable expansion of diagnostic products for antibiotic resistance in STIs.
The test detects SARS-CoV-2 from nasopharyngeal swab specimens and runs on standard qPCR instruments, including Thermo Fisher's Applied Biosystems 7500 Fast machine.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.
Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.